Dr. Giles Hartman, MRCP (UK), DipRCPath (UK) was born in Johannesburg in 1970 and raised in Cape Town. He graduated among South Africa’s top matriculants before earning his medical degree with honors from the University of Cape Town and completing his internship at Groote Schuur Hospital. In 1995, he moved to the United Kingdom, achieving Membership of the Royal College of Physicians (MRCP) and training under Professor Richard Wise in Birmingham, where he began specialization in infectious diseases and medical microbiology through the Royal College of Pathologists. This culminated in a Wellcome Trust Fellowship held jointly at the Universities of Oxford (as Visiting Scientist) and Bristol (as Honorary Lecturer) but was centered on the Functional Genomics capabilities at the Wellcome Trust Genome Campus in Cambridge that housed the Sanger Center, European Bioinformatics Institute and the Human Genome Mapping Project. His research focussed on genome-wide microarray gene expression analysis of both host (human, rat and mouse) and bacterial pathogen during their interaction in cell co-culture infection models. Due to the complex mixture of pro- and eukaryotic genetic material arising from co-culture, Dr Hartman developed and refined laboratory protocols for RNA isolation, enrichment and amplification which are now available as commercial kits.
Dr. Hartman’s research on antimicrobial chemotherapy pharmacokinetics and pharmacodynamics, notably with moxifloxacin, has contributed to international dosing standards and regulatory approval, while as a co-author of influential systematic reviews on antimicrobial stewardship, he has helped shape global policy frameworks such as the ORION guidelines as well as lay the foundation for Cochrane reviews on antibiotic prescribing and stewardship.
During the final year of the Wellcome Fellowship, he returned to South Africa to lead HIV/AIDS programs as Chief Medical Officer at Settlers Hospital, ultimately introducing the US PEPFAR Partnership Framework to South Africa and initiating nationwide adoption of its antiretroviral centric programme as a predominantly nurse-led initiative. The subsequent availability of antiretrovirals has undoubtedly contributed to reversing the low South African life expectancy impact caused by the HIV/AIDS pandemic.
Surviving a life-changing event, Dr. Hartman transitioned to pastoral and humanitarian work, founding the global New Creation Church Network International in 2025. His career reflects a lifelong commitment to equitable healthcare, scientific rigor, and service to vulnerable communities.
